Ardelyx Inc.

0.8530+0.0330+4.02%Vol 2.45M1Y Perf -50.30%
Aug 5th, 2022 16:00 DELAYED
BID0.8213 ASK0.8662
Open0.7500 Previous Close0.8200
Pre-Market- After-Market0.86
 - -  0.00 0.56%
Target Price
4.83 
Analyst Rating
Moderate Buy 1.67
Potential %
466.24 
Finscreener Ranking
★★     44.53
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     38.28
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     52.50
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
25.37 
Earnings Rating
Strong Buy
Market Cap123.34M 
Earnings Date
4th Aug 2022
Alpha-0.03 Standard Deviation0.20
Beta1.80 

Today's Price Range

0.73010.8700

52W Range

0.49021.92

5 Year PE Ratio Range

-2.90-5.20

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
22.21%
1 Month
36.83%
3 Months
5.30%
6 Months
6.65%
1 Year
-50.30%
3 Years
-62.26%
5 Years
-82.23%
10 Years
-

TickerPriceChg.Chg.%
ARDX0.85300.03304.02
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
ProfitabilityValueIndustryS&P 500US Markets
97.90
-3 739.10
-3 707.70
-2 042.30
-
RevenueValueIndustryS&P 500US Markets
2.67M
0.02
121.17
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.19-0.190.00
Q01 2022-0.20-0.21-5.00
Q04 2021-0.25-0.31-24.00
Q03 2021-0.34-0.42-23.53
Q02 2021-0.36-0.45-25.00
Q01 2021-0.32-0.34-6.25
Q04 2020-0.26-0.32-23.08
Q03 2020-0.28-0.2028.57
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.195.00Positive
9/2022 QR-0.199.52Positive
12/2022 FY-0.725.26Positive
12/2023 FY-0.342.86Positive
Next Report Date-
Estimated EPS Next Report-0.19
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume2.45M
Shares Outstanding144.60K
Shares Float143.08M
Trades Count5.21K
Dollar Volume1.98M
Avg. Volume1.83M
Avg. Weekly Volume1.56M
Avg. Monthly Volume1.57M
Avg. Quarterly Volume2.37M

Ardelyx Inc. (NASDAQ: ARDX) stock closed at 0.853 per share at the end of the most recent trading day (a 4.02% change compared to the prior day closing price) with a volume of 2.45M shares and market capitalization of 123.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 88 people. Ardelyx Inc. CEO is Michael G. Raab.

The one-year performance of Ardelyx Inc. stock is -50.3%, while year-to-date (YTD) performance is -22.45%. ARDX stock has a five-year performance of -82.23%. Its 52-week range is between 0.4902 and 1.92, which gives ARDX stock a 52-week price range ratio of 25.37%

Ardelyx Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 1.58, a price-to-sale (PS) ratio of 36.74, a price to cashflow ratio of 58.30, a PEG ratio of 2.32, a ROA of -93.35%, a ROC of -105.17% and a ROE of -163.10%. The company’s profit margin is -%, its EBITDA margin is -3 707.70%, and its revenue ttm is $2.67 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Ardelyx Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. Ardelyx Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Ardelyx Inc. is Moderate Buy (1.67), with a target price of $4.83, which is +466.24% compared to the current price. The earnings rating for Ardelyx Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ardelyx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ardelyx Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.35, ATR14 : 0.07, CCI20 : 243.75, Chaikin Money Flow : 0.16, MACD : 0.03, Money Flow Index : 77.05, ROC : 15.76, RSI : 59.81, STOCH (14,3) : 92.45, STOCH RSI : 1.00, UO : 60.22, Williams %R : -7.55), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ardelyx Inc. in the last 12-months were: David P. Rosenbaum (Sold 67 640 shares of value $44 916 ), Elizabeth Grammer (Sold 63 147 shares of value $41 644 ), Forest Baskett (Sold 2 881 570 shares of value $3 642 571 ), Jeffrey Jacobs (Sold 13 661 shares of value $14 813 ), Justin A. Renz (Sold 77 914 shares of value $51 398 ), Michael G. Raab (Sold 121 157 shares of value $81 684 ), Robert Blanks (Sold 83 015 shares of value $54 816 ), Sandell D Scott (Sold 2 881 570 shares of value $3 642 571 ), Susan Rodriguez (Sold 52 018 shares of value $34 621 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (66.67 %)
4 (57.14 %)
4 (57.14 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (33.33 %)
3 (42.86 %)
3 (42.86 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.86
Moderate Buy
1.86

Ardelyx Inc.

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

CEO: Michael G. Raab

Telephone: +1 510 745-1700

Address: 34175 Ardenwood Boulrvard, Fremont 94555, CA, US

Number of employees: 88

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

70%30%

Bearish Bullish

66%34%


News

Stocktwits